Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 4/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | HPGD | P15428 | 2/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.72 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.64 |
| ▸ | PTGER2 | P43116 | 3/20 | 0.64 |
| ▸ | PTGIR | P43119 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.64 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.64 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prostaglandin A1 SCHEMBL6417551 | 1.00 | TRPA1 (1.00) | TRPA1NR4A2MEN1LMNAHPGD | |
| Prostaglandin A1 SCHEMBL11650631 | 1.00 | TRPA1 (1.00) | TRPA1NR4A2MEN1LMNAHPGD | |
| Prostaglandin A1 SCHEMBL17914205 | 1.00 | TRPA1 (1.00) | TRPA1NR4A2MEN1LMNAHPGD | |
| Prostaglandin A1 SCHEMBL3366007 | 1.00 | TRPA1 (1.00) | TRPA1NR4A2MEN1LMNAHPGD | |
| Prostaglandin A1 SCHEMBL14577651 | 1.00 | TRPA1 (1.00) | TRPA1NR4A2MEN1LMNAHPGD | |
| Prostaglandin A1 SCHEMBL23717317 | 1.00 | TRPA1 (1.00) | TRPA1NR4A2MEN1LMNAHPGD | |
| Prostaglandin A1 SCHEMBL6417548 | 1.00 | TRPA1 (1.00) | TRPA1NR4A2MEN1LMNAHPGD | |
| Prostaglandin A1 SCHEMBL13649323 | 1.00 | TRPA1 (1.00) | TRPA1NR4A2MEN1LMNAHPGD | |
| Prostaglandin A1 SCHEMBL22425783 | 1.00 | TRPA1 (1.00) | TRPA1NR4A2MEN1LMNAHPGD | |
| Prostaglandin A1 SCHEMBL8347690 | 1.00 | TRPA1 (1.00) | TRPA1NR4A2MEN1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036195-B2 | Co-crystals of NURR1-lbd in complex with a cyclopentenone prostaglandin and modulators of NURR1 | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2024-07-16 | — | — | US | disclosed |
| US-12036195-B2 | Co-crystals of NURR1-lbd in complex with a cyclopentenone prostaglandin and modulators of NURR1 | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2024-07-16 | — | — | US | disclosed |
| US-11883413-B2 | Inhibition of thymine DNA glycosylase in the treatment of cancer | INSTITUT CURIE (FR) | 2024-01-30 | — | — | US | disclosed |
| US-20220054500-A1 | Inhibition of Thymine DNA Glycosylase in the Treatment of Cancer | INSTITUT CURIE (FR) | 2022-02-24 | — | — | US | disclosed |
| EP-3052655-B1 | CLOSANTEL IN COMBINATION WITH TEMOZOLOMIDE FOR USE IN THE TREATMENT OF A CANCER IN WHICH IS THYMINE DNA GLYCOSYLASE EXPRESSED | INSTITUTE FOR CANCER RES D/B/A THE RES INSTITUTE OF FOX CHASE CANCER CENTER (US) | 2018-11-07 | — | — | EP | disclosed |
| US-5877215-A | Method of treating neoplastic cells with prostaglandin and radiation treatment or prostaglandin and platinum-based anti-tumor agents | MEDICAL UNIVERSITY OF SOUTH CAROLINA (US) | 1999-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036195-B2 | Co-crystals of NURR1-lbd in complex with a cyclopentenone prostaglandin and modulators of NURR1 | NCOR1, NCOA1, NR0B1 | TRPA1 2781/4885NR4A2 13/4885MEN1 4811/4885 |
| US-20220054500-A1 | Inhibition of Thymine DNA Glycosylase in the Treatment of Cancer | UNG, MPG, TYMP | TRPA1 4772/4885NR4A2 2676/4885MEN1 1230/4885 |
| US-11883413-B2 | Inhibition of thymine DNA glycosylase in the treatment of cancer | UNG, MPG, TYMP | TRPA1 4772/4885NR4A2 2676/4885MEN1 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.